

# NEWS RELEASE



**Veritas In Silico**



September 16, 2025

Company Name: **Veritas In Silico Inc.**

Representative: Shingo NAKAMURA,

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact Person: Tsuneo GODA,

Executive Officer, General Manager,

Corporate Planning Division

Email: [ir@veritasinsilico.com](mailto:ir@veritasinsilico.com)

## Nomination of a Candidate for Independent Outside Director

Veritas In Silico, Inc., hereafter referred to as "the Company", has announced that the board of the Company has decided to nominate a candidate for Independent Outside Director as follows. Please note that it will be formally confirmed upon election as a director in the Company's 10th Annual General Shareholders' Meeting, scheduled in March 2026.

### ● Name, Brief Career History, and Reasons for Nomination

Name (Date of Birth): Ms. Tomoko SATO, Ph.D. (December 15, 1954)

#### Brief Career History

April 1977	Nippon Roche K.K. (currently CHUGAI PHARMACEUTICAL CO., LTD.) Nippon Roche Research Center, Kamakura, Principal Researcher, Biological Screening Group
August 1995	Doctorate Obtained from Ochanomizu University Doctor of Science (Ph.D.)
July 1998	Bayer Yakuhin Ltd. Research Center Kyoto, Head of Screening Technology Department
July 2003	Bayer Yakuhin Ltd. Head of Business Development & Licensing Division
February 2012	MSD K.K. Executive Director, Scientific Partnering
January 2021	Schrödinger K.K. President and Representative Director
May 2025	Veritas In Silico, Inc. Advisor (Current Position)

Reason for Nomination: Ms. Tomoko SATO has amassed approximately 50 years of extensive practical experience and specialized knowledge in the pharmaceutical

industry. As the Company continues to expand its operations both domestically and internationally, Ms. SATO is well-positioned to provide ongoing guidance and counsel based on her extensive experience and expertise. In her role as an Independent Outside Director, she will also contribute to the management of the Company from an objective standpoint. The Company anticipates that its corporate governance structure will be further strengthened by her nomination.

\* After the election of Ms. Tomoko SATO as a director, the Company intends to file her as an Outside Independent Director with the Tokyo Stock Exchange.

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>